A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.

Br J Cancer · 2006 · PMC2361326 · PMID 16670714

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

A large placebo-controlled phase III study in patients with advanced NSCLC who had received one or two prior chemotherapy regimens, IRESSA Survival Evaluation in Lung Cancer (ISEL), showed some improvement in overall survival with single-agent gefitinib that failed to reach statistical significance compared with placebo in the overall or adenocarcinoma co-primary populations.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.